Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » Executive Summary – Process Optimization for Monoclonal Antibody (mAb) Commercial Manufacturing

Executive Summary - Process Optimization for Monoclonal Antibody (mAb) Commercial Manufacturing

Summary: Process characterization and validation is an important step in the product development journey and late-phase development. In some cases, process optimization is required for an existing manufacturing process before process characterization begins. Catalent will share a case study of a monoclonal antibody (mAb) from clinical to commercial phase under a highly compressed timeline. This presentation highlights the strategic plan Catalent executed to meet the needs of the program without sacrificing the thorough scientific evaluation of the process required for a successful validation campaign.

 

Click here to download the Executive Summary